SG11202106049RA - Mutated piggybac transposase - Google Patents

Mutated piggybac transposase

Info

Publication number
SG11202106049RA
SG11202106049RA SG11202106049RA SG11202106049RA SG11202106049RA SG 11202106049R A SG11202106049R A SG 11202106049RA SG 11202106049R A SG11202106049R A SG 11202106049RA SG 11202106049R A SG11202106049R A SG 11202106049RA SG 11202106049R A SG11202106049R A SG 11202106049RA
Authority
SG
Singapore
Prior art keywords
mutated
piggybac transposase
piggybac
transposase
mutated piggybac
Prior art date
Application number
SG11202106049RA
Other languages
English (en)
Inventor
Neeraj J Agrawal
Kristine M Daris
Jennitte L Stevens
Huong Thi Ngoc Le
Noelia Blanco Talavan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11202106049RA publication Critical patent/SG11202106049RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/463Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632T-cell receptors [TCR]; antibody T-cell receptor constructs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07Nucleotidyltransferases (2.7.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/90Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202106049RA 2018-12-10 2019-12-09 Mutated piggybac transposase SG11202106049RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862777325P 2018-12-10 2018-12-10
US201962925516P 2019-10-24 2019-10-24
PCT/US2019/065129 WO2020123327A1 (fr) 2018-12-10 2019-12-09 Transposase piggybac ayant subi une mutation

Publications (1)

Publication Number Publication Date
SG11202106049RA true SG11202106049RA (en) 2021-07-29

Family

ID=69143664

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106049RA SG11202106049RA (en) 2018-12-10 2019-12-09 Mutated piggybac transposase

Country Status (14)

Country Link
US (1) US20220064610A1 (fr)
EP (1) EP3894549B1 (fr)
JP (1) JP7441840B2 (fr)
KR (1) KR20210101270A (fr)
CN (1) CN113195712A (fr)
AU (1) AU2019398101A1 (fr)
BR (1) BR112021011063A2 (fr)
CA (1) CA3121268A1 (fr)
CL (1) CL2021001488A1 (fr)
IL (1) IL283314A (fr)
MX (1) MX2021006783A (fr)
SG (1) SG11202106049RA (fr)
TW (1) TW202035687A (fr)
WO (1) WO2020123327A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122716A1 (fr) * 2021-12-22 2023-06-29 Vanderbilt University Transpososomes de nouvelle génération
WO2023212697A1 (fr) 2022-04-28 2023-11-02 Immatics US, Inc. Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation
WO2023212655A1 (fr) 2022-04-28 2023-11-02 Immatics US, Inc. Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation
WO2023212691A1 (fr) 2022-04-28 2023-11-02 Immatics US, Inc. Polypeptides récepteurs de tgfβ négatifs dominants, polypeptides cd8, cellules, compositions et leurs méthodes d'utilisation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1990005183A1 (fr) 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
ATE275628T1 (de) 1996-01-11 2004-09-15 Immunex Corp Expressionssteigernde sequenzelemente (ease) für eukaryontische expressionssysteme
CA2196496A1 (fr) 1997-01-31 1998-07-31 Stephen William Watson Michnick Epreuve de complementation de fragments de proteines pour la detection d'interactions entre proteines
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2406864A1 (fr) 2000-02-24 2001-08-30 Xcyte Therapies, Inc. Stimulation et concentration simultanees de cellules
US7932088B1 (en) * 2005-04-25 2011-04-26 University Of Notre Dame Du Lac High efficiency transformation of Plasmodium falciparum by the lepidopteran transposon, piggyBac
US20110311506A1 (en) 2009-02-25 2011-12-22 The Johns Hopkins University Piggybac transposon variants and methods of use
WO2010099296A1 (fr) * 2009-02-26 2010-09-02 Transposagen Biopharmaceuticals, Inc. Transposases piggybac hyperactives
US20100311116A1 (en) 2009-06-04 2010-12-09 Excellgene Sa Fast generation of high expression stable cell lines expressing recombinant proteins under minimal and short-term selective pressure
WO2011146862A1 (fr) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Méthodes d'induction d'une apoptose sélective
GB201014169D0 (en) 2010-08-25 2010-10-06 Cambridge Entpr Ltd In vitro hepatic differentiation
ES2700966T3 (es) 2010-12-09 2019-02-20 Univ Pennsylvania Utilización de linfocitos T modificados con receptores de antígeno quiméricos para tratar el cáncer
CN103502438A (zh) 2011-03-23 2014-01-08 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
WO2013012824A2 (fr) 2011-07-15 2013-01-24 The Johns Hopkins University Transposases piggybac de trichoplusia ni à activité d'intégration réduite
CN103360464A (zh) * 2013-07-17 2013-10-23 武汉摩尔生物科技有限公司 多肽、编码该多肽的dna分子、载体、制备方法及应用
US10563225B2 (en) 2013-07-26 2020-02-18 President And Fellows Of Harvard College Genome engineering
US20150291975A1 (en) * 2014-04-09 2015-10-15 Dna2.0, Inc. Enhanced nucleic acid constructs for eukaryotic gene expression
EP3018200A1 (fr) 2014-11-07 2016-05-11 Fondazione Matilde Tettamanti e Menotti de Machi Onlus Procédé amélioré pour la production de cellules génétiquement modifiées
US20230183884A1 (en) 2016-11-30 2023-06-15 China Agricultural University A method for crispr library screening

Also Published As

Publication number Publication date
KR20210101270A (ko) 2021-08-18
CL2021001488A1 (es) 2021-11-26
JP2022512332A (ja) 2022-02-03
US20220064610A1 (en) 2022-03-03
IL283314A (en) 2021-07-29
JP7441840B2 (ja) 2024-03-01
MX2021006783A (es) 2021-07-15
BR112021011063A2 (pt) 2021-08-31
CA3121268A1 (fr) 2020-06-18
EP3894549B1 (fr) 2024-07-31
AU2019398101A1 (en) 2021-06-10
TW202035687A (zh) 2020-10-01
EP3894549A1 (fr) 2021-10-20
WO2020123327A1 (fr) 2020-06-18
CN113195712A (zh) 2021-07-30

Similar Documents

Publication Publication Date Title
HUE062942T2 (hu) Akkumulátordoboz
ZAA201701984S (en) Grooming apparatus
ZAA201701983S (en) Grooming apparatus
HUE061187T2 (hu) Akkumulátordoboz
IL283314A (en) Pibbybac transposase is flushed
ZAA201701979S (en) Grooming apparatus
ZAA201701978S (en) Grooming apparatus
IL283057A (en) Converted isoindolinones
IL280913A (en) New methods
CA185160S (en) Box
HUE065047T2 (hu) Akkumulátorház
IL280912A (en) New methods
GB201803724D0 (en) Methods
GB201806174D0 (en) Improved downlighter
GB2564808B (en) Drivetrains
GB201802486D0 (en) Methods
SG11202007342QA (en) Methods
GB201909661D0 (en) Early entry
GB201805466D0 (en) Methods
IL273728A (en) Beta-lactamase zovariants
GB201814451D0 (en) Methods
GB201817010D0 (en) Methods
ZA201902106B (en) Teaching
GB201815435D0 (en) Methods
GB201815358D0 (en) Methods